Loading…
← CockpitCompetitor Analysis › 7924.TWO TLC BioSciences CorpOpen in the cockpit ↗

TLC BioSciences Corp7924.TWOCompetitor analysis, valuation and peers

Taiwan · TWD·Health Care›Biotechnology

Taiwan Liposome Company (TLC), a Taiwan biotech that reformulates drugs using proprietary liposome/lipid-based drug-delivery technology.

≈ A Taiwanese peer to Pacira BioSciences (liposomal drug reformulation)
Mkt cap
$1.50B
US dollars, full cap
$/day
$4.73M
20-day average traded
Fwd P/E
n/m
no positive forecast
ROIC−WACC
n/a
Hurdle
n/a
no reverse DCF
Close · TWDNT$391.50
1D+4.4%
1W-2.7%
1M-7.5%
3M+65.2%
6Mn/a
YTDn/a
1Yn/a
ATR %8.7%
52w lowhigh22.2% off high

What TLC BioSciences does

Taiwan Liposome Company (TLC), a Taiwan biotech that reformulates drugs using proprietary liposome/lipid-based drug-delivery technology.

In one line: A Taiwanese peer to Pacira BioSciences (liposomal drug reformulation).

Products and services

  • Liposome-based reformulated drugs
  • Drug-delivery platform licensing

Customers

  • Pharmaceutical licensing partners
  • Hospitals/clinics (via approved products)

Where it sits in the supply chain

  • Health Care
  • Biotechnology
  • Liposomal drug reformulation & delivery

What could go right

  • Regulatory approvals and licensing deals for pipeline products

What could go wrong

  • Clinical/regulatory risk
  • Reliance on licensing partners for commercialization

Moat: narrow (IP / patents, process know-how). Proprietary liposome formulation technology used to extend or improve existing drugs, patent-protected.

Headquarters: Taipei, Taiwan · Founded: 1997

Named competitors

  • Pacira BioSciences PCRX
  • Ipsen IPN.PA

TLC BioSciences at a glance

Size TLC BioSciences (7924.TWO) is a Taiwan Health Care company (Biotechnology) with a market value of $1.50B, the 201st largest of 648 Taiwan companies the cockpit tracks. Shares closed at NT$391.50 on 18 Nov 2026.

TLC BioSciences competitors and peer comparison

Head to head with its named competitors (7924.TWO vs PCRX vs IPN.PA)
CompanyMarket cap6M returnRevenue growthOp. marginEV / SalesReq g
TLC BioSciences 7924.TWO$1.50Bn/an/an/an/an/a
Pacira Biosciences PCRXn/a+55%n/an/an/an/a
Ipsen IPN.PA$14.8B+1%+14%30%3.1×-6.7%

How TLC BioSciences compares with its peers

Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.

TLC BioSciences against its 20 peers (data as of 18 Nov 2026)
Measure7924.TWOPeer medianRank in peer set
1-month return-7.5%-10.9%7th highest of 21
Distance from 52-week high-22.2%-44.5%2nd highest of 21

Peer table

Peer set: Industry: the same industry and sector in any market, nearest in size
CompanyMarketMarket cap6M returnRevenue growthOp. marginEV / SalesReq gDelivered g
TLC BioSciences 7924.TWOTaiwan$1.50Bn/an/an/an/an/an/a
Chengdu Olymvax Biopharmaceuticals 688319.SSChina$1.51B-37%+12%8%13.1×n/an/a
Korsana Biosciences KRSAUnited States$1.52B+54%-64%-5,277%1,058.7×n/an/a
Peptron 087010.KSSouth Korea$1.49B-68%-13%-488%359.6×n/an/a
Mesoblast MSB.AXAustralia$1.49B-17%+556%-43%12.8×n/an/a
Kailera Therapeutics KLRAUnited States$1.53B-41%n/an/an/an/an/a
Precigen PGENUnited States$1.53B0%+2,388%21%10.1×n/an/a
Fujian Haixi Pharmaceuticals 2637.HKHong Kong$1.47B-32%+25%33%n/an/an/a
Nurix Therapeutics NRIXUnited States$1.54B-14%+739%41%0.8×n/an/a
UroGen Pharma URGNUnited States$1.46B-1%+159%-12%6.3×n/an/a
Wuhan Healthgen Biotechnology 688765.SSChina$1.46B-51%+90%-297%205.0×n/an/a
Vir Biotechnology VIRUnited States$1.57B+3%+1,696%-70%4.0×n/an/a
Immunocore Holdings Plc Shs Sponsored American Depositary Shares Repr 1 Sh IMCRUnited States$1.44B-7%+13%-7%2.3×n/an/a
Nanjing Vazyme Biotech 688105.SSChina$1.42B+25%+16%-5%4.9×39.4%-2.5%
uniQure QUREUnited States$1.42B-17%+28%-1,027%65.4×n/an/a
Absci ABSIUnited States$1.41B+65%-47%-9,155%835.7×n/an/a
PolyPeptide PPGN.SWSwitzerland$1.61B+7%+22%7%3.4×n/an/a
AnaptysBio ANABUnited States$1.40B-22%+13%62%7.9×0.5%+25.6%
PELL Bio-Med Technology 6949.TWTaiwan$1.62B+28%+8%-1,463%1,650.2×n/an/a
Hitgen 688222.SSChina$1.62B-3%+42%27%14.4×33.2%+16.8%
Alvotech ALVOUnited States$1.62B+38%-14%12%6.4×n/an/a

Questions

Who are TLC BioSciences's main competitors?
Named competitors: Pacira BioSciences (PCRX), Ipsen (IPN.PA). The cockpit's measured peer set (industry) also includes Chengdu Olymvax Biopharmaceuticals (688319.SS), Korsana Biosciences (KRSA), Peptron (087010.KS), Mesoblast (MSB.AX), Kailera Therapeutics (KLRA), Precigen (PGEN).

How these numbers are made. Returns are close-to-close in local currency. Revenue growth and margins are trailing twelve months. Req g is the revenue growth that today's enterprise value requires for seven years at the company's own cost of capital; Delivered g is what it actually grew; the gap is the hurdle (honest precision about ±8 points, so read the ranking more than the decimal). No fair values, price targets or analyst ratings are shown, by design. Method and validation.